Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

In vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients

CANDIMAD study: a prospective multi-centre laboratory based survey of antifungal resistance in Candida spp. causing invasive candidiasis in Madrid

Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

Delayed Initiation of the Novel Oral Glucan Synthase Inhibitor, Ibrexafungerp, is Effective in a Murine Model of Invasive Candidiasis caused by Candida auris

Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi

Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including Isolates with Elevated MIC’s to Echinocandins

Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)

Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal Candidiasis and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)